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Background: Embryonic stem cells (ESCs) are pluripotent stem cells and can form tumors containing cells from all
three germ layers. Similarities between pluripotent stem cells and malignant tumor cells have been identified. The
purpose of this study was to obtain ESCs-converted tumor cell lines and to investigate the mechanism of
malignancy in pluripotent stem cells.
Methods: Mouse ESCs were subcutaneously injected into nude mice to obtain tumors from which a tumor-like cell
line (ECCs1) was established by culturing the cells in chemical-defined N2B27 medium supplied with two small
molecular inhibitors CHIR99021 and PD0325901 (2i). The ECCs1 were then subcutaneously injected into nude mice
again to obtain tumors from which another tumor-like cells line (ECCs2) was established in the same 2i medium.
The malignant degree of ESCs, ECCs1 and ECCs2 was compared and the underlying mechanism involved in the
malignancy development of ESCs was examined.
Results: The three ESCs, ECCs1 and ECCs2 cell lines were cultured in the same 2i condition and showed some
likeness such as Oct4-expression and long-term expansion ability. However, the morphology and the
tumor-formation ability of the cell lines were different. We identified that ECCs1 and ECCs2 gradually acquired
malignancy. Moreover, Wnt signaling-related genes such as CD133 and β-catenin expression were up-regulated and
Frizzled related protein (FRP) was down-regulated during the tumor development of ESCs.
Conclusions: The two tumor-like cell lines ECCs1 and ECCs2 stand for early malignant development stage of ESCs
and the ECCs2 was more malignant than the ECCs1. Moreover, we identified that Wnt/β-catenin signaling played
an important role in the malignancy process of ESCs.
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Embryonic stem cells (ESCs) are pluripotent stem cell
which can develop into normal individuals after being
injected into blastocysts [1-3]. ESCs can form tumors
after being injected into nude mice [4], which is a secur-
ity barrier for cell replacement therapy of ESCs. Recently,
several groups reported that significant signatures related
to ESCs were also identified in many human cancers and
in mouse cancer models [5-9], indicating that tumorigen-
esis might start at an early ‘embryonic’ state. Classical* Correspondence: qianqj@sino-gene.cn
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reproduction in any medium, provided the orviews of tumorigenesis have invoked tissue dedifferenti-
ation in the oncogenic process, whereas modern views
assume that tumor initiating cells might arise from stem
cells or from the dedifferentiation of somatic cells. Som-
atic cells have been reprogrammed to induced pluripo-
tent stem cells (iPSCs) by transduction of defined
transcription factors such as Oct4 [10-13] and the gener-
ation of mammalian offspring after somatic cell nuclear
transfer (SCNT) have been obtained [14,15]. These
results showed that somatic cell can be reprogrammed
into ESCs-like pluripotent stem cells and then convert
into the tumor initiating cells. Thus, establishment of
ESCs-converted tumor cell lines will provide excellent
models for researching the mechanism of tumorigenesis
and new approaches for cancer therapy. In this study,
ESCs was subcutaneously injected into nude mice totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was derived. ECCs1 were then subcutaneously injected
into nude mice to form tumors again, from which an-
other tumor-like cell line ECCs2 was established. Our
results indicated that ECCs1 showed a tendency of ma-
lignant and ECCs2 was more malignant than ECCs1.
Furthermore, ECCs1 and ECCs2 could maintain Oct4-
expression. Recent researches have already examined the
overlapping features that are shared by ESCs and tumor
cells [8,16,17], indicated that expression of Oct4 is poten-
tially correlated with malignancy and may impact on
some aspects of tumor behavior. Moreover, we also
found that a cancer stem cell marker [18] CD133
expressed in ECCs2 which is regarded as a Wnt/β-catenin
target gene. We then validated the expression of several
key target genes in Wnt/β-catenin signaling pathway.
It showed that β-catenin up-regulated during the
malignance of ESCs and expression of Frizzled related
protein (FRP) down-regulated with the progress of ma-
lignancy. FRP interact with Wnt proteins, antagonizing
Wnt/β-catenin signaling [19]. Wnt/β-catenin signaling
improved Oct4-expression and self-renewal ability of
human and mouse ESCs [20]. Furthermore, Wnt/β-
catenin signaling play a key role in differentiation and
maintenance of ESCs in vitro [21], and it also play a
central function in transforming normal stem cells into
cancer stem cells [22-24], all of which verified that
Wnt/β-catenin signaling can be utilized both in the acqui-
sition of pluripotency and in tumorigenesis.
Although some similarities between the pluripotent
stem cells and tumor cells have been identified, ESCs-
converted tumors cell lines need to be established to
study the mechanism involved in the earliest tumorigen-
esis, moreover, further researches need to be performed
to solve difficult problems in this field including the cur-
rently culture system for ESCs and tumor cells are dif-
ferent. In this study, we maintained mouse ESCs in
chemical defined N2B27 medium supplied with two
small molecular inhibitors CHIR99021 and PD0325901
(2i) as previously described [25]. The ECCs1 and ECCs2
were also maintained in the same chemical-defined 2i
medium. Moreover, the two cell lines maintained long-
term self-renewal ability in 2i and spontaneously
obtained malignancy without transferring viral or tran-
scription factors. We believe that establishment of these
cell lines may provide concise models for researching
the mechanism of carcinogenesis in ESCs.
Methods
Maintenance of ESCs
The ESCs were maintained in N2B27 medium supplied
with two inhibitor (2i): CHIR99021 (STEMGENT) and
PD0325901 (STEMGENT) as previously described [25].
Other culture medium and growth factors were purchasedfrom Invitrogen. The ESCs were detached using 0.05%
trypsin every three days, with a split ratio of 1 to 10.
N2B27 is a 1:1 mixture of Dulbecco’s minimal essential
medium (DMEM)/F12 and Neurobasal medium supplied
with 1% Glutamax, 1 ×N2 and 1×B27. 2i is N2B27
medium supplied with 3 μm/ml CHIR99021 and
0.4 μm/ml PD0325901. The culture medium was changed
by half every day. Cells were maintained at 37°C, 5% CO2
and 100% humidity.
Tumors induction and establishment of ECCs1
Nude mice were purchased from Shanghai Experimental
Animal Center, Chinese Academy of Sciences. All animal
experiments were carried out in adherence with the Na-
tional Institutes of Health Guidelines on the Use of La-
boratory Animals and approved by the Second Military
Medical University Committee on Animal Care (EC11-
055). The ESCs were dissociated into single-cell and sus-
pended in phosphate-buffered saline (PBS), each nude
mouse was subcutaneously injected 5 × 106 cells to pro-
duce tumor. When the diameter of tumors was up to
1.5 cm, the mice were sacrificed. The tumors were
removed from the sacrificed nude mice and washed each
three times in PBS and then cut into 1cubic millimeter
pieces. After digesting by collagenase IV for 30 min at
37°C, the cell suspension was filtered through 200-mesh
sieve and centrifuged for 3 min at 100 g. Then the cells
were suspended in 2i medium and plated onto 96-well
plate in single cell, several days later, the single cell-
formed clone was picked up and propagated. The estab-
lished cell line was named ECCs1.
Establishment of ECCs2
Cells from ECCs1 were dissociated and suspended in
PBS, each nude mouse was subcutaneously injected
5 × 106 cells to produce tumor. When the diameter of
tumors was up to 1.5 cm, the mice were sacrificed. Der-
ivation of cells from the ECCs1-converted tumors was
same with the derivation of ECCs1. The cells were cul-
tured in 2i medium in single cell, several days later, the
single cell-formed clone was picked up and propagated.
The established cell line was named ECCs2.
Malignancy analysis of ESCs, ECCs1 and ECCs2-formed
tumors
Differentiation ability of ESCs, ECCs1 and ECCs2 was
determined by switching these cells from 2i medium to
DMEM medium supplied with 10% fetal bovine serum
(FBS). For hematoxylin and eosin (H&E) staining, tissues
from ESCs, ECCs1 and ECCs2-converted tumors were
separately preserved in 4% paraformaldehyde for 24 h,
and then the samples from each group were embedded
in paraffin, sectioned, and stained with H&E. Karyotype
analysis was performed according to previous study [26].
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We fixed the ESCs, ECCs1 and ECCs2 cells in 4% paraf-
ormaldehyde for 20 min at 20°C individually, then
washed the cells three times × 10 min with PBS and
incubated them in blocking buffer (BB)(0.2% Triton X-
100, 1% BSA) in PBS for 1 h at 20°C. Then, the cells
were separately incubated with a primary antibody, anti-
goat Oct4 (Santa Cruz, sc-8629) or anti-mouse CD133
(eBioscience, 14133180) at a dilution of 1:200 for 12 h at
4°C, the cells were then washed three times × 10 min
with PBS and incubated with secondary antibody at a di-
lution of 1:500 for 1 h at 20°C and washed three
times × 10 min with PBS. The cells were incubated with
0.5 μg/ml diamino phenyl indole (DAPI) for five min for
staining of nuclei for total cell content.
Western blot analysis
All the cell lysates (5 × 106) were collected and homoge-
nized in radioimmunoprecipitation buffer (Pierce) sup-
plied with protease inhibitor cocktail (Roche) for 30 min
at 4°C. Protein concentrations were determined by a
Bicinchoninic Acid Protein Assay Kit (Thermo) and the
amounts of protein were normalized for quantification..
Protein preparations were resolved on a 10% SDS-
polyacrylamide gel and then transferred to nitrocellulose
membranes (Protran, Schleicher and Schuell). The mem-
branes were rinsed and probed with the following anti-
bodies at a dilution of 1:1000: β-catenin (BD
Transduction Laboratories, 610153), FRP1 (Santa Cruz,Figure 1 ESCs, ECCs1 and ECCs2 in 2i medium. (A) ESCs in 2i (left), imm
2i (left), immunostaining of Oct4 (red), ECCs1-converted tumors (right). (C)
tumors (right). DAPI (blue) staining of nuclei for total cell content.sc-13939), standard was tubulin (Sigma T9026,). Blots
were visualized using enhanced chemiluminescence
(Amersham) and quantified with a Kodak gel documen-
tation system. The Western data were analysised and
quantified by using GeneSys software (SynGene)
Cell growth curve
Cell growth curves of ESCs, ECCs1 and ECCs2 in differ-
ent culture medium (2i or DMEM supplied with 10%
FBS) were determined. Cells from each group were sep-
arately cultured in 24-well plates at a density of 1,000
cells per well. Every 24 h, three of the wells from each
group were harvested using 0.05% trypsin and the num-
ber of cells per well was counted with a hematocyt-
ometer. This procedure was repeated for 7 days.
Statistical analysis
Statistical analysis was performed by using SPSS 11.0.
Results are presented as means and standard deviation
(SD), and a value of P < 0.05 was considered statistically
significant. The paired Student t test was calculated to
compare the values between each group.
Results and discussion
ESCs, ECCs1 and ECCs2 maintained Oct4 expression in 2i
medium
The mouse ESCs were cultured in chemical-defined 2i
medium as previously described [25]. Figure 1A showed
that the ESCs grew in clone and maintained Oct4-unostaining of Oct4 (red), ESCs-converted tumors (right). (B) ECCs1 in
ECCs2 in 2i (left), immunostaining of Oct4 (red), ECCs2-converted
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their characteristics over numerous passages in 2i
medium. After being injected into nude mice, the ESCs
formed tumors measuring up to 1.5 cm in diameter within
7–8 weeks (Figure 1A). Then, the mice were sacrificed
and tissues obtained from the tumors were dissociated
into single cell and cultured in 2i medium. The dissociated
cells grew abundantly in 2i medium. We picked up a sin-
gle cell-formed clone and named the clone ECCs1
(Figure 1B). Although the ECCs1 was cultured in the same
culture condition with the ESCs, the ECCs1 displayed cel-
lular disarrangement and the morphology of ECCs1 was
gradually different with the ESCs (Figure 1B). The ECCs1
also maintained Oct4-expression in 2i medium
(Figure 1B). We already maintained the cells more than 50
passages and the cells still grew abundantly in 2i medium.
Then, we injected the ECCs1 into nude mice again. The
ECCs1 formed tumors measuring up to 1.5 cm in diam-
eter within 6–7 weeks (Figure 1B). The mice were then
sacrificed and tissues from the ECCs1-formed tumors
were dissociated into single cell and cultured in 2i
medium. Several days later, a single-cell clone was picked
up and named as ECCs2 whose morphology was com-
pletely different from that of ESCs (Figure 1C). The
ECCs2 did not grow in separate clone but showed over-
lapping growth and cellular disarrangement. As well as
ESCs and ECCs1, Figure 1C showed that the ECCs2 still
maintained Oct4-expression in 2i medium and long-term
self-renewal ability. After being injected into nude mice,
the ECCs2 could form tumors measuring up to 1.5 cm in
diameter within 4 weeks. Taken together, these results
indicated that ECCs1 and ECCs2 were different from
ESCs and showed a tendency of malignancy.
It is well known that ESCs could form tumors after
being injected into nude mice and the tumors are mainly
composed of normal cells and tissues from three germ
layers [4]. However, our results indicated that Oct4-
possitive cells still existed in the ESCs-formed tumors.
Moreover, in our previous study, we also injected a well
established Oct4-GFP knock-in mouse ESCs [27] into
nude mice to form tumors and several Oct4-positives cell
lines were derived from the tumors by using the 2i
medium [28]. We purposed that there were several fac-
tors that facilitated the derivation of the Oct4-possitive
cells. First, in this study, we cut the ESCs-formed tumors
into 1cubic millimeter pieces and different samples from
the tumors were collected for deriving ECCs1 and
ECCs2. Second, most of differentiated cells could not
survive in the serum-free 2i medium. Third, the 2i
medium includes small molecular inhibitor CHIR99021
and PD0325901. CHIR99021 is a GSK3 inhibitor [29]
and previous studies showed that inhibition of GSK3
plays an important role in maintaining Oct4-expression
and overall cell survival ability [20,25]. PD0325901 is aninhibitor of mitogen-activated protein kinase signaling
which induces differentiation of ESCs [30]. The 2i
medium was first applied to derive mouse ESCs [25]. In
this study, we applied 2i medium to derive and maintain
the two ECCs1 and ECCs2 cell lines. Although we cul-
tured the ESCs, ECCs1 and ECCs2 in the same 2i culture
condition, the morphology and the tumor-formation
ability of the three cell lines were totally different
(Figure 1). In our previous study, we also performed
microarray analysis to show that many well-known
tumor-associated genes change with the malignancy de-
velopment of ESCs after sequential transplantation [28].
Taken together, these results indicated that the subcuta-
neous microenvironment of nude mice could accelerate
the malignancy degree of ESCs. We proposed that the
two tumor-like ECCs1 and ECCs2 cell lines might stand
for the early tumor development stage of ESCs.
ECCs1 and ECCs2 gradually acquired malignant
The two tumor-like lines ECCs1 and ECCs2 were estab-
lished via monoclonal formation (Figure 2A). Even after
repeated passage in 2i medium, the karyotype analysis
showed that the ECCs2 maintained normal chromosome
number (Figure 2A) at early passage (Passage 19).
We then evaluated the likeness and difference among
ESCs, ECCs1 (Passage 14) and ECCs2 (Passage 15). The
three cell lines shared several same characteristics such as
Oct4-expression and self-renewal ability in 2i medium.
However, after withdrawal of 2i, the ESCs could not main-
tain long-term self-renewal ability. The ESCs differen-
tiated into embryonic body in DMEM medium supplied
with 10% FBS (Figure 2B) and Oct4-expression of the
ESCs quickly disappeared (Figure 2C). The results con-
firmed that the ESCs maintained a balance of self-renewal
and differentiation, after withdrawal of 2i inhibitors, the
ESCs quickly converted into normal differentiated cells.
We observed that the ECCs1 grew abundantly and differ-
entiated partially in DMEM medium supplied with 10%
FBS (Figure 2B), some of which still maintained Oct4-
expression for 2–3 passages (Figure 2C). The results indi-
cated that the ECCs1 had a tendency of malignancy. After
withdrawal of 2i, the ECCs2 maintained Oct4-expression
in DMEM medium supplied with 10% FBS (Figure 2C)
even after long-term expansion and repeated passages
(Figure 2B) which verified that ECCs2 lost the appropriate
regulatory mechanisms to maintain a balance of self-
renewal and differentiation.
The cell growth curve assay confirmed that ESCs,
ECCs1 and ECCs2 grew abundantly and maintained ex-
ponential growth in 2i medium (Figure 2D) with statisti-
cally no significant difference among each group. After
withdrawal of 2i, the cell growth curve showed that the
differentiated ESCs had two phases of growth: an expo-
nential phase with a steady-state exponential growth and
Figure 2 ESCs, ECCs1 and ECCs2 in DMEM supplied with 10% FBS. (A) tumor-derived cells seeded as single cells (left) Single cell-formed
ECCs2 clone (middle), ECCs2 maintained normal karyotype at early passage(right). (B) ESCs (left), ECCs1 (middle) and ECCs2 (right) in DMEM
supplied with 10% FBS. (C) Immunostaining of Oct4 (green) and DAPI (blue) of ESCs (left), ECCs1 (middle) and ECCs2 (right). (D) Growth curve of
ESCs, ECCs1 and ECCs2 in 2i medium. (E) Growth curve of ESCs, ECCs1 and ECCs2 in DMEM supplied with 10% FBS. *,P < 0.05 versus ESCs;{,
P < 0.05 versus ESCs and versus ECCs1. Each point represents a mean of triplicate values for each sample ± SD.
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(Figure 2E). The growth curve of ECCs1 also showed the
growth rate of ECCs1 was significant (P < 0.05) higher
than that of ESCs (Figure 2E). However, the cell growth
curve of ECCs2 only showed an exponential growth
phase in DMEM supplied with FBS (Figure 2E) and thegrowth rate of ECCs2 was significant higher (P < 0.05)
than that of ESCs and ECCs1 (Figure 2E). Taken together,
these results showed that ECCs2 acquired malignancy
and lost differentiation ability.
We then fixed tissues from the ESCs, ECCs1 and
ECCs2-converted tumors to examine the malignancy
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showed that the ESCs-formed tumors were mainly com-
posed of normal cells and tissues from the three germ
layers (Figure 3A) including muscle, bone, glandular and
neural tissues. The ECCs1-formed tumors still included
tissues such as muscle, gland and bone, however, the
tumors showed a malignant tendency of hyperchromatic
nuclei and cellular derangement (Figure 3B). The ECCs2-
formed tumors were mainly composed of poorly differen-
tiated adenocarcinoma and carcinomatous nerve tissue
(Figure 3C). Moreover, the H&E staining results con-
firmed that ECCs1 showed a tendency of malignancy and
ECCs2 was malignant tumor cells. Therefore, we
assumed that ECCs1 was intermediates between the
ESCs and ECCs2. These results also indicated that the
characteristics of these cell lines were profoundly influ-
enced by microenvironment and the subcutaneous
microenvironment of nude mice accelerated the malig-
nancy degree of the ESCs. On the other hand, embryonicFigure 3 H&E staining. (A) Muscle (left), bone (middle), neural and gland
and gland (right) tissues of ECCs1-formed tumors. (C) ECCs2-formed tumormicroenvironment suppresses the tumorigenic pheno-
type of aggressive cancer cells proved by several previous
works [31,32]. Other studies showed that there is a con-
vergence between malignant tumor cells and embryonic
cells in the molecular messengers including members of
Notch and Wnt signaling [33,34]. Our results also
excluded the possibility that the tumorigenesis of ECCs2
was caused by the loss of chromosomes.
We then evaluated the chromosome number of ECCs2
at late passage (Passage 53). Interestingly, the ECCs2 was
established by clone-formation and maintained normal
chromosome number at early passage (Figure 2A), how-
ever, ECCs2 showed a loss of chromosomes at late passage
(Passage 53) and chromosome number of some ECCs2
was around 38~39 (Additional file 1: Figure S1). We pro-
posed that deletion and amplification of genes and signal-
ing played a role in increasing the rate of chromosome
mutations and then the abnormal mitotic mechanisms
may result in numerical aberrations in the daughter cells.(right) tissues in ESCs-formed tumors. (B) Muscle (left), bone (middle)
s.
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like cell lines in which ECCs1 showed a tendency of ma-
lignancy and ECCs2 was malignant tumor cells. The two
cell lines provided models for studying the convergence of
tumorigenic and embryonic signaling pathways and then
might help to identify new targets for therapeutic
intervention.
Wnt/β-Catenin signaling has a relationship with the
malignancy of ESCs
To clarify the difference between ESCs and ECCs2, we
performed immunostaining to detect the expression of
CD133, a common marker for the identification of stem
cells from normal and cancerous tissues [35,36]. The
immunostaining results showed that CD133 expression in
ESCs was negative (Figure 4A), however, most of ECCs2
showed expression of CD133 (Figure 4B), the results also
indicated that the ECCs2 was different from the ESCs.
CD133 is regarded as a target gene of Wnt/β-catenin
signaling pathway [18]. Previous researches point out thatFigure 4 Wnt/β-catenin signaling in carcinogenesis of ESCs. (A) Immu
CD133 (red) in ECCs2. (C) β-catenin-expression in ESCs, ECCs1 and ECCs2. (inappropriate activation of the Wnt/β-catenin pathway
implicate in transforming normal stem cells into cancer
stem cells [22-24,37], however, the role of Wnt/β-catenin
signaling in ESCs carcinogenesis remains unclear. In our
previous study [28], we also noted that some of Wnt
signaling-associated genes changed with the malignancy
development of ESCs. We then examined the expression
of β-catenin in ESCs, ECCs1 and ECCs2. The western blot
results showed that expression of β-catenin was strongly
activated in the ECCs1 and ECCs2 compared with ESCs
(Figure 4C). The Western data were also quantified by
using GeneSys software and the results confirmed that
Wnt/β-catenin signaling was activated during malignant
development of ESCs (Additional file 2: Figure S2). Fur-
thermore, we also detected another Wnt signaling related
protein, FRP1. It is reported that FRP antagonize with
Wnt signaling and down-regulation of FRP activate Wnt
signaling [19]. The western blot result showed that FRP1
was obviously down-regulated in ECCs1 and ECCs2
(Figure 4D). Expression of FRP1 was also quantified bynostaining of DAPI (blue) and CD133 (red) in ESCs. (B) DAPI (blue) and
D) FRP1-expression in ESCs, ECCs1 and ECCs2.
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pression of FRP1 was gradually reduced during the malig-
nant development of ESCs (Additional file 2: Figure S2).
According to the results, we assumed that β-catenin might
act as a molecular switch in carcinogenesis of ESCs. Pos-
sible function of Wnt/β-catenin signaling might include
up-regulation of target gene, disruption of linked signal-
ing, deregulation of cell proliferation and disruption of cell
adhesion [38]. In summary, our results indicated that
down-regulation of FRP1 activated Wnt/β-catenin signal-
ing, up-regulation of β-catenin facilitated the expression
of Oct4 in ECCs1 and ECCs2 and then promoted malig-
nancy of these cells. However, it was still unclear which
gene regulated the expression of FRP1 during the carcino-
genesis of ESCs. In future, we would study and compare
more involved genes in Wnt/β-catenin signaling. Also, the
iPSCs can form tumors in nude mice [11,12]. It will be
useful to establish iPSCs-converted tumor cell lines and
our work provides a simple protocol for establishing the
pluripotent stem cells-converted tumor cell lines. The
chemical-defined culture condition will provide a precise
platform for studying the carcinogenesis mechanism of
pluripotent stem cells.
Conclusions
In this study, we established two ESCs-originated tumor-
like cell lines ECCs1 and ECCs2, the ECCs1 and ECCs2
could maintain long-term self-renewal ability in 2i
medium. Second, our results showed that the ECCs2 was
malignant tumor cells and ECCs1 was intermediates be-
tween the ESCs and ECCs2, while subcutaneously injec-
tion in nude mice accelerated the malignancy of these
cells. Third, our work also indicated that Wnt/β-catenin
signaling played an important role in the process of malig-
nancy of these cell lines.
Additional files
Additional file 1: Figure S1. Karyotype analysis of ECCs2 at passage 53.
Additional file 2: Figure S2. Western data were quantified by using
GeneSys software. The value of spot1 ~ 12 stands for the western blot
data respectively, Spot 13 stands for the negative control.
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